[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,103
  • Shares Outstanding, K 147,372
  • Annual Sales, $ 6,690 K
  • Annual Income, $ -39,780 K
  • EBIT $ 0 M
  • EBITDA $ -37 M
  • 60-Month Beta 2.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/04/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 359.37% (-133.44%)
  • Historical Volatility 60.05%
  • IV Percentile 71%
  • IV Rank 24.91%
  • IV High 1,253.85% on 02/12/26
  • IV Low 62.69% on 10/03/25
  • Expected Move (DTE 10) 0.3145 (71.09%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 86
  • Volume Avg (30-Day) 205
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 6,523
  • Open Int (30-Day) 5,753
  • Expected Range 0.1279 to 0.7569

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3465 +27.68%
on 06/11/26
0.4504 -1.78%
on 07/06/26
+0.0658 (+17.47%)
since 06/05/26
3-Month
0.2928 +51.09%
on 04/13/26
1.0499 -57.86%
on 04/15/26
+0.0824 (+22.89%)
since 04/06/26
52-Week
0.2928 +51.09%
on 04/13/26
3.5299 -87.47%
on 12/08/25
-1.2776 (-74.28%)
since 07/03/25

Most Recent Stories

More News
Immutep Completes FDA Project Optimus, Advances Efti Trials

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immutep (...

IMMP : 0.4424 (+4.98%)
Immutep Announces Favorable Safety Profile for First-in-Class LAG-3 Agonist IMP761 in Phase I Trial

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025.Quiver AI SummaryImmutep Limited has released promising initial safety...

IMMP : 0.4424 (+4.98%)
Immutep Reports Promising Clinical Results for Efti in Combination with Pembrolizumab in Patients with Difficult-to-Treat Head and Neck Cancer

Immutep reports promising clinical results for efti combined with pembrolizumab in treating difficult head and neck cancer patients.Quiver AI SummaryImmutep Limited has announced promising clinical results...

IMMP : 0.4424 (+4.98%)

Business Summary

Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the...

See More

Key Turning Points

3rd Resistance Point 0.4921
2nd Resistance Point 0.4713
1st Resistance Point 0.4568
Last Price 0.4424
1st Support Level 0.4215
2nd Support Level 0.4007
3rd Support Level 0.3862

See More

52-Week High 3.5299
Fibonacci 61.8% 2.2933
Fibonacci 50% 1.9114
Fibonacci 38.2% 1.5294
Last Price 0.4424
52-Week Low 0.2928

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.